Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Krish Patel; Youngil Koh; Sabarish Ayyappan; Yasmin Karimi; Izidore S. Lossos; Akil Merchant; Phuong Lee; Jianhua Jin; Raphael Clynes; Jitendra Kanodia; Michael T. Chiarella; Steve Kye; Jean-Marie Michot

doi:10.1182/blood-2022-158042

$Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL$

Journal article

Peer reviewed

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Krish Patel, Youngil Koh, Sabarish Ayyappan, Yasmin Karimi, Izidore S. Lossos, Akil Merchant, Phuong Lee, Jianhua Jin, Raphael Clynes, Jitendra Kanodia, …

Blood, Vol.140(Supplement 1), pp.12066-12067

2022-11-15

DOI: https://doi.org/10.1182/blood-2022-158042

Appears in Miller School of Medicine - Latest Publications

Metrics

1 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.204 Molecular & Cell Biology - Immunotherapy; 1.204.1334 Phage Display
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL
Creators: Krish Patel - 1Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WA
Youngil Koh - Seoul National University Hospital
Sabarish Ayyappan - University of Iowa Hospitals and Clinics
Yasmin Karimi - University of Michigan–Ann Arbor
Izidore S. Lossos - Sylvester Comprehensive Cancer Center
Akil Merchant - Cedars-Sinai Medical Center
Phuong Lee - 7Xencor, Inc., Monrovia, CA
Jianhua Jin - 7Xencor, Inc., Monrovia, CA
Raphael Clynes - 7Xencor, Inc., Monrovia, CA
Jitendra Kanodia - 7Xencor, Inc., Monrovia, CA
Michael T. Chiarella - 7Xencor, Inc., Monrovia, CA
Steve Kye - 7Xencor, Inc., Monrovia, CA
Jean-Marie Michot - Institut Gustave Roussy
Publication Details: Blood, Vol.140(Supplement 1), pp.12066-12067
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031786614302976